Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Eyenovia, Inc. develops innovative ophthalmic delivery platforms, primarily the Optejet, for precise microdosing of eye medications. Its core products include FDA-approved Mydcombi for pupil dilation and licensed clobetasol propionate for post-surgical inflammation. The company focuses on improving treatment efficacy, safety, and patient compliance through targeted, low-volume delivery systems, leveraging digital health integration and strategic licensing in ophthalmology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.